Pfizer will acquire Arixa Pharmaceuticals to advance the development of oral antibiotics.

Pfizer's hospital business has now agreed to buy Arixa, the next-generation oral antibiotic company that is working to develop drug-resistant Gloria-negative infections, announced yesterday (October 22).
the financial terms of the acquisition have not been disclosed.
Arixa's lead compound, ARX-1796, is an oral drug presuperance of the new β endamidease inhibitor avibactam, a β-endamidease inhibitor (BLI) approved by the FDA in 2015.
as part of Avycaz® products (sold by Pfizer outside the United States under the name Zaficefta® ) to treat a variety of adaptive disorders caused by Gloren's negative bacterial infection through intravenous combination cephalosporine.
based on Arixa's existing licensed technology, Avibactam prescient drugs can achieve a 60-80% absorption effect in Phase I clinical trials when the patient is taking the drug, releasing FDA-approved Avibactam molecules in the blood.
, direct oral Avibactam can only achieve about 7% of the blood absorption effect.
As a result of increased drug resistance, common Glone-negative bacterial infections, such as complex urinary tract infections, are becoming major therapeutic challenges, with more and more patients being forced to inject drugs intravenously because they cannot be treated with oral antibiotics.
β-endamidease inhibitor combination has become the main means of antimicrobial therapy, and clavulanic acid, approved by the FDA in 1984, is currently the only orally inhibited antibiotic.
, however, Avibactam has a broader inhibition of β-endamidease produced by bacteria by antibiotics such as penicillin, cephalosporin and carbon penicillin than kravitic acid.
Arixa management sees Pfizer as the ideal company to incorporate ARX-1796 into subsequent clinical trials and to advance the development of Arixa's leading asset, AX-1796, to be eventually approved for use in patients in need.
Arixa is currently committed to being a fully virtual company with no employees, with virtually no administrative costs, all through the CRO model, under the supervision of a group of part-time expert consultants, and the ARX-1796 research and development process is driven by this model.
" Pfizer will develop the ARX-1796, which, if approved, will be used in combination with antibiotics such as cephalosporine, potentially becoming the first new oral β-endamidease inhibitor-antibiotic combination in 35 years to treat urinary tract and other infections.
source: Arixa Pharmaceuticals Announcs By Pfizer's Hospital Business.